Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Clot-Busting drug boost heart attack recovery?

NCT ID NCT03335839

Disease control Sponsor: Population Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a low dose of the clot-busting drug tPA directly into the heart arteries, during standard angioplasty, improves blood flow and reduces complications in people having a major heart attack. 210 patients were enrolled. The goal was to see if this approach could reduce heart damage and improve outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tissue plasminogen activator (tPA)
What this could lead to
If it works, this could improve blood flow and reduce heart damage during a heart attack, potentially lowering the risk of death or heart failure.
What could go wrong
This is a completed Phase 3 trial with 210 participants, so results are limited. Adding tPA may increase bleeding risk, and the benefit may not be large enough to change standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

210 people

The number who actually took part.

Started

Apr 2018

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with STEMI undergoing primary PCI and, 2. ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and, 3. Randomization within 6 to 12 hours of symptom onset and, 4. Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing. Exclusion Criteria: 1. Active internal bleeding or high risk of bleeding or any prior intracranial bleeding. 2. Any other absolute or relative contraindication to fibrinolytic therapy. 3. Administration of a fibrinolytic ≤24hrs prior to randomization. 4. Cardiogenic shock on presentation. 5. Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment resolution, an outcome of the study). 6. Planned upfront use of a glycoprotein IIb/IIIa inhibitor. 7. Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction Percutaneous coronary intervention

Contacts and locations

Locations

  • Hamilton General Hospital

    Hamilton, Ontario, L8L2X2, Canada

  • University of Alberta - Mazankowski Alberta Heart Insitute

    Edmonton, Alberta, T6G 2B7, Canada

  • University of Calgary - Foothills Medical Centre

    Calgary, Alberta, T2N 4Z6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.